These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 36315955)

  • 1. In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.
    Kelsey MD; Newby LK
    Ann Intern Med; 2022 Nov; 175(11):JC126. PubMed ID: 36315955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ezetimibe plus moderate-intensity statin versus high-intensity statin.
    Drug Ther Bull; 2023 Mar; 61(3):38. PubMed ID: 36813278
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.
    Kim BK; Hong SJ; Lee YJ; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Cho YH; Lee SJ; Ahn CM; Kim JS; Ko YG; Choi D; Jang Y; Hong MK;
    Lancet; 2022 Jul; 400(10349):380-390. PubMed ID: 35863366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
    Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS;
    JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.
    Lee SH; Lee YJ; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Park KH; Lee JH; Choi YJ; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    J Am Coll Cardiol; 2023 Apr; 81(14):1339-1349. PubMed ID: 37019580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Effectiveness of High-Intensity Statins Versus Low/Moderate-Intensity Statins Plus Ezetimibe in Patients With Atherosclerotic Cardiovascular Disease for Reaching LDL-C Goals: A Systematic Review and Meta-Analysis.
    Soleimani H; Mousavi A; Shojaei S; Tavakoli K; Salabat D; Farahani Rad F; Askari MK; Nelson J; Ruzieh M; Hosseini K
    Clin Cardiol; 2024 Aug; 47(8):e24334. PubMed ID: 39135464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial.
    Lee YJ; Lee SH; You SC; Lee YH; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    Diabetes Obes Metab; 2024 Mar; 26(3):829-839. PubMed ID: 37994242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial.
    Lee YJ; Cho JY; You SC; Lee YH; Yun KH; Cho YH; Shin WY; Im SW; Kang WC; Park Y; Lee SY; Lee SJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Kim JS
    Eur Heart J; 2023 Mar; 44(11):972-983. PubMed ID: 36529993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial.
    Lee B; Hong SJ; Rha SW; Heo JH; Hur SH; Choi HH; Kim KJ; Kim JH; Kim HK; Kim U; Choi YJ; Lee YJ; Lee SJ; Ahn CM; Ko YG; Kim BK; Choi D; Hong MK; Jang Y; Kim JS
    Atherosclerosis; 2023 Dec; 386():117373. PubMed ID: 37995599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis.
    Hameed I; Shah SA; Aijaz A; Mushahid H; Farhan SH; Dada M; Khan AB; Amjad R; Alvi F; Murtaza M; Zuberi Z; Hamza M
    Am J Cardiovasc Drugs; 2024 May; 24(3):419-431. PubMed ID: 38578578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of moderate-intensity statin with ezetimibe combination vs. high-intensity statin therapy according to sex in patients with atherosclerosis.
    Kim BG; Lee SJ; Lee YJ; You SC; Hong SJ; Yun KH; Hong BK; Heo JH; Rha SW; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Cho YH; Kim JS
    Sci Rep; 2023 Nov; 13(1):20157. PubMed ID: 37978309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there benefit to adding ezetimibe to a statin for the secondary prevention of CVD?
    Reddy V; Allison J; Mounsey A
    J Fam Pract; 2023 Jun; 72(5):227-229. PubMed ID: 37339492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Statin/Ezetimibe for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Asian Populations: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Bhagavathula AS; Aldhaleei WA; Al Matrooshi NO; Rahmani J
    Clin Drug Investig; 2020 Sep; 40(9):809-826. PubMed ID: 32671595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review.
    Gudzune KA; Monroe AK; Sharma R; Ranasinghe PD; Chelladurai Y; Robinson KA
    Ann Intern Med; 2014 Apr; 160(7):468-76. PubMed ID: 24514899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of ezetimibe and moderate-intensity statin for patients with atherosclerotic cardiovascular disease: a paradigm shift in lipid management landscape.
    Pedicino D; Volpe M
    Eur Heart J; 2022 Nov; 43(41):4227-4228. PubMed ID: 36101476
    [No Abstract]   [Full Text] [Related]  

  • 17. Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.
    Lee SJ; Joo JH; Park S; Kim C; Choi DW; Hong SJ; Ahn CM; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Nam CM; Hong MK
    J Am Coll Cardiol; 2023 Aug; 82(5):401-410. PubMed ID: 37495276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed Combination for the Treatment of Dyslipidaemia.
    Ferri N; Ruscica M; Santos RD; Corsini A
    Curr Atheroscler Rep; 2023 Oct; 25(10):691-699. PubMed ID: 37715044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: A meta-analysis of randomized controlled studies.
    Ah YM; Jeong M; Choi HD
    PLoS One; 2022; 17(3):e0264437. PubMed ID: 35245303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.